Hedge fund manager Bill Ackman and designer Neri Oxman announced the Ackman Oxman Institute (AOI) on 19-20 August 2026, a New York-based non-profit brain research institute seeded with roughly $400 million in Pershing Square Inc. stock, with a stated further commitment of similar or greater size in a form other than Pershing Square stock. Per Fortune’s coverage, focus areas are brain research, rehabilitation, recovery, human optimization, and longevity. Mount Sinai in New York is one of AOI’s clinical partners, alongside others.
Ackman said in his announcement that the institute was inspired by the recovery of his 26-year-old daughter Lucy, who was found unconscious in a Brooklyn apartment in February 2026 after a massive brain haemorrhage, approximately 15 hours after the bleed. Ackman said Lucy has regained cognition, is beginning to walk with assistance, but remains unable to see. Per Yahoo Finance’s 21 August 2026 coverage, Ackman said Lucy’s own recovery may eventually involve brain-computer interface technology from companies including Neuralink, Precision Neuroscience, Science Corp, Synchron, and Nudge. Lucy is therefore a possible future BCI recipient, not only the personal motivation behind AOI’s founding.
The vehicle
AOI is structured as a non-profit research institute with an integrated venture capital arm. Ackman and Oxman have described the model as deliberately built outside the elite university system, on the argument that top research talent is leaving those institutions. Anchor real estate for the institute is two Upper West Side buildings acquired by Ackman’s foundation for $260 million in July 2026, per West Side Rag coverage of that transaction. Per Yahoo Finance, the campus is roughly 680,000 square feet on Manhattan’s West End Avenue, a footprint Ackman said is larger than Rockefeller University. AOI plans to prioritise cures, treatments, devices, rehabilitation and exercise equipment over academic publishing. Ackman expects to name a CEO for AOI by October 2026.
The named board reported in Fortune’s coverage combines science, operators, and clinicians: inventor Dean Kamen, Regeneron co-founder and Chief Scientific Officer George Yancopoulos, Nobel laureate biochemist James Rothman, Harvard neuroscientist Bernardo Sabatini, neurosurgeon Chris Kellner (who Yahoo Finance reports has led Lucy Ackman’s care team), and Pershing Square Foundation CEO Olivia Flatto, alongside Ackman and Oxman.
The BCI companies Ackman cited
Ackman named five BCI companies in his announcement as examples of the field AOI will engage with: Neuralink, Precision Neuroscience, Synchron, Science Corp and Nudge. Ackman did not state that AOI is taking equity in any of these companies. Reporting has not established any equity relationship.
Neuralink, Precision Neuroscience, Synchron and Science Corp are established names in the US commercial BCI cohort that InsideBCI covers regularly. Nudge is the newest of the five: a non-invasive focused-ultrasound neuromodulation startup co-founded by Coinbase co-founder Fred Ehrsam and Quintin Frerichs, with a $100 million Series A led by Thrive Capital and Greenoaks Capital. Nudge’s product is called Nudge Zero. Its inclusion alongside the four implanted-BCI operators indicates AOI’s scope covers both invasive and non-invasive modalities across the BCI field.
The commercial pattern
Private capital compounding around brain research and BCI through founder-adjacent philanthropy is not new. Elon Musk owns Neuralink directly. Meta founder Mark Zuckerberg’s Chan Zuckerberg Initiative funds neuroscience research. Amazon founder Jeff Bezos’s family office and adjacent vehicles have made neurotech-adjacent commitments. AOI is the latest and one of the largest single announcements in this pattern, and it explicitly positions itself outside the Ivy and MIT-Stanford orbit.
For readers tracking capital flowing into BCI: this is philanthropic capital designated for research and rehabilitation, sitting alongside the equity capital flowing directly into companies. It does not compress the commercial-equity market for BCI operators. It does add a durable US non-profit sponsor with a stated multi-hundred-million-dollar commitment and a clinical partner at Mount Sinai.
What is not disclosed
The exact legal structure of AOI’s non-profit-plus-venture-capital hybrid is not fully specified in public coverage. Measurable research milestones, KPIs, or grant-making pipeline are not disclosed. Whether AOI’s venture arm will take equity positions in the named BCI operators, or in other neurotech companies, is not stated. Any exclusive or preferred relationship with a specific BCI operator, if it exists, is not disclosed.
Lucy Ackman’s medical detail beyond what her father has shared publicly is not part of this coverage.
What to watch
The first named research programme or grant from AOI. A public grant announcement will be the first indicator of where AOI’s capital actually deploys, versus the founding narrative.
Any hire announcement for AOI’s scientific leadership beyond the founding board. Named institute director, chief medical officer, and head of the venture arm will define the operating profile.
Whether AOI’s venture arm makes a first equity commitment into a named BCI operator. A single named investment would shift AOI from philanthropic sponsor to active commercial capital in the BCI category.